parkinsons drugs Flashcards
parkinsons
1) dopaminergic neuron degeneration
2) paralysis agitans, shaking palsy
3) decreased number of neurons in the substantia nigra
alzheimers
1) neurons in brain degenerate
parkinsons etiology
1) SNCA gene regulates synaptic vesicles in presynaptic terminals
2) mutations will cause misfolding, leading to death of dopaminergic neurons in substantia nigra
3)AD or AR
parkinsonism
symptoms which may occur due to anti-dopaminergic drugs (anti-psychotics)
motor pathways
1) pyramidal tract (A) controls voluntary movements
2) extrapyamidal tract (B)
- posture, balance, tonus, smooths fine voluntary movements
dopamine transporter scan
1) DAT
2) activity can be detected
- red is fast, green is slow
diagnosis
1) premotor
- reduced smell, speech
- impulsive behavior
- changes of thinking
- sleep disturbance
- constipation
2) motor
- resting tremor
- postural rigidity
- postural instability
nigrostriatal pathway in norma and PD
1) dopaminergic neurons inhibit GABAergic neurons
- whereas cholinergic and glutaminergic neurons produce excitatory effects
2) in PD< abnormally high output by GABAergic efferents
- increased inhibition of thalamus and reduced excitatory input to motor cortex
pharmacotherapy of PD
1) redress DA levels
- supply precursor for DA (levodopa)
- stimulate DA receptors
2) reduce cholinergic activity in striatum
levodopa
1) precursor of DA
- useful in 2/3 of PD for 2-3 years
2) carbadopa makes L-dopa more stable in blood
l-dopa side effects
1) overdose cause schizophrenia like symptoms
2) uncontrolled movements (on-off effects)
3) anorexia, nausea, vomiting
5) tachycardia, postural hypotension
carbidopa
1) adjunct with L-dopa
2) allows 4-5 fold lower dose of L-dopa, reduce side effects
COMT inhibitors
1) COMT inactivates dopamine
2) tolcapone and entacapone will inhibit COMT
3) used in combo with l-dopa
dopamine receptor agonists
1) activate the dopamine receptors in striatum directly
2) apomorphine, bromocriptine, amantadine
MAO-B inhibitors
1) rasagiline, salagiline
2) inhibit deactivation of dopamine